Search
Now showing items 21-25 of 25
Developing RAS-binding antibody-derived hit compounds
(Institute of Cancer Research (University Of London), 2023-09-27)
Exploring an oncolytic virus triggered PD-L1 response via immunoPET
(Institute of Cancer Research (University Of London), 2023-01-23)
Oncolytic virotherapy (OV) exploits viruses which preferentially infect and kill cancerous cells. Moreover, oncolytic viruses stimulate the tumour-immune microenvironment towards an inflammatory phenotype. Therefore, OV ...
Elucidating Prostate Cancer Immunopathology and Immunogenomics Utilizing Computational Analyses of Digital Imaging
(Institute of Cancer Research (University Of London), 2024-01-05)
Prostate Cancer (PCa) is a prominent non-cutaneous malignancy in men in developed countries, necessitating effective treatments. Chronic inflammation is a key factor in PCa pathogenesis and progression, involving a ...
Identification and characterisation of drug-tolerant persister cells arising in response to targeted CHK1 inhibition
(Institute of Cancer Research (University Of London), 2024-01-05)
Drug-tolerant persisters (DTPs) are a subpopulation of slow-cycling cells that have been identified in several cancer cell lines following lethal exposure to targeted and cytotoxic therapeutics and shown to precede acquisition ...
Lysine-targeting covalent inhibitors
(Institute of Cancer Research (University Of London), 2023-12-14)
Targeted Covalent Inhibitors (TCIs) represent an increasingly important strategy in modern drug discovery. TCIs exploit high affinity, reversible ligands which are then modified with modestly-reactive electrophilic warheads ...